HK Stock MarketDetailed Quotes


16.840 -1.180-6.55%
Market Closed 09/28 16:08 CST

About 3D MEDICINES Company

3D Medication Inc. ( is a pharmaceutical company focusing on the field of cancer treatment that has entered the commercialization stage. Adhering to the vision of “helping cancer patients live longer and better”, combined with the future trend of chronic cancer treatment, it develops next-generation oncology drugs for cancer patients around the world. The company's product line includes 12 innovative drug candidates with clinical value and differentiated or global leadership. Of these, 8 have entered clinical development or commercialization, including the world's first new PD-L1 monomonial antibody drug, which has been conditionally approved by the China Drug Administration to be marketed in China; the introduction of the first-in-class polypeptide tumor vaccine 3D189 and the Gas6/AXL inhibitor 3D229 has been approved by the FDA for global phase III MRCT clinical research; the self-developed multi-target kinase inhibitor 3D011 has also entered clinical trials In the development phase, the other 4 products targeting FGFR123\ EP4\ COX2\ CD47 respectively have also entered the clinical stage at home and abroad. Preclinical varieties also include the internationally leading dual antibody CD3xPD-L1. The company currently has an international team of more than 250 people in the development, production and commercialization of new drugs to explore better treatments for cancer patients around the world.

Company Profile

Company Name3D MEDICINES
Listing Date12/15/2022
Issue Price24.98
Shares Offered16.35M share
RegistrationCayman Islands
ChairmanZhaolong Gong
SecretaryFang\lijingyi Xia
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeCricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands
Head Office and Principal Place of Business14th Floor, Golden Dragon Centre, 188 Des Voeux Road Central, Hong Kong
Fiscal Year Ends12-31
MarketHong Kong motherboard
Business 3D Tumor Biotechnology Shanghai Co Ltd is a Chinese company mainly engaged in research and development of commercialized oncology products and drug candidates. The company's main product pipeline includes immuno-oncology monotherapy, drug candidates whose mechanism of action is suitable for combination within the pipeline, and pain management assets. The company's core product is subcutaneous injection of the anti-PD-L1 drug nwolimumab. The company also has a number of clinical-stage drug candidates, including peptide cancer vaccine 3D189, GAS6 decoy receptor 3D229, and fibroblast growth factor receptor (FGFR) 3D185. The company mainly operates in the domestic market.

Company Executives

No Data

Paper Trade Start
LMT Order
Claim up to $1 million virtual fund, join moomoo paper trading today! Claim Now >